ATE336247T1 - Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten - Google Patents
Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheitenInfo
- Publication number
- ATE336247T1 ATE336247T1 AT03704902T AT03704902T ATE336247T1 AT E336247 T1 ATE336247 T1 AT E336247T1 AT 03704902 T AT03704902 T AT 03704902T AT 03704902 T AT03704902 T AT 03704902T AT E336247 T1 ATE336247 T1 AT E336247T1
- Authority
- AT
- Austria
- Prior art keywords
- sub
- selective
- img
- prodrug
- character
- Prior art date
Links
- 239000000018 receptor agonist Substances 0.000 title abstract 4
- 229940044601 receptor agonist Drugs 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229940002612 prodrug Drugs 0.000 abstract 3
- 239000000651 prodrug Substances 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010019663 Hepatic failure Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010030043 Ocular hypertension Diseases 0.000 abstract 1
- 210000003017 ductus arteriosus Anatomy 0.000 abstract 1
- 208000007903 liver failure Diseases 0.000 abstract 1
- 231100000835 liver failure Toxicity 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36571102P | 2002-03-18 | 2002-03-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE336247T1 true ATE336247T1 (de) | 2006-09-15 |
Family
ID=28042041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03704902T ATE336247T1 (de) | 2002-03-18 | 2003-03-06 | Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7414071B2 (de) |
| EP (1) | EP1487437B1 (de) |
| JP (1) | JP2005531516A (de) |
| AT (1) | ATE336247T1 (de) |
| AU (1) | AU2003207900A1 (de) |
| BR (1) | BR0308738A (de) |
| CA (1) | CA2478653A1 (de) |
| DE (1) | DE60307607T2 (de) |
| ES (1) | ES2268327T3 (de) |
| MX (1) | MXPA04005555A (de) |
| TW (1) | TW200304816A (de) |
| WO (1) | WO2003077910A1 (de) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE281432T1 (de) | 1999-03-05 | 2004-11-15 | Univ Duke | C-16 ungesätigte fp-selektive prostaglandin analoge |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
| AU2011202937B2 (en) * | 2002-05-14 | 2012-06-07 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| US6573294B1 (en) * | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| GB0219143D0 (en) * | 2002-08-16 | 2002-09-25 | Univ Leicester | Modified tailed oligonucleotides |
| US7256211B1 (en) | 2003-01-21 | 2007-08-14 | Ono Pharmaceutical Co., Ltd. | 8-azaprostaglandin derivatives and medical use thereof |
| US6734206B1 (en) * | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| JP2007512347A (ja) * | 2003-11-26 | 2007-05-17 | デューク・ユニバーシティー | 緑内障を予防するかまたは治療する方法 |
| DE602005025755D1 (de) | 2004-06-04 | 2011-02-17 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
| AU2005252171A1 (en) * | 2004-06-04 | 2005-12-22 | Allergan, Inc. | Piperidinyl prostaglandin analogs as ocular hypotensive agents |
| JP2008518013A (ja) * | 2004-10-26 | 2008-05-29 | アラーガン、インコーポレイテッド | プロスタグランジンｅｐ４アゴニストによる処置方法およびデリバリー方法 |
| WO2006052893A2 (en) | 2004-11-08 | 2006-05-18 | Allergan, Inc. | Substituted pyrrolidone compounds as ep4 agonists |
| ATE515263T1 (de) * | 2005-05-06 | 2011-07-15 | Allergan Inc | Substituierte beta-lactame und deren verwendung in der medizin |
| US7674786B2 (en) | 2005-05-06 | 2010-03-09 | Allergan, Inc. | Therapeutic β-lactams |
| WO2006121822A1 (en) * | 2005-05-06 | 2006-11-16 | Allergan, Inc. | USE OF β-LACTAMS FOR THE TREATMENTOF IBD AND GLAUCOMA |
| US7893107B2 (en) | 2005-11-30 | 2011-02-22 | Allergan, Inc. | Therapeutic methods using prostaglandin EP4 agonist components |
| UY30121A1 (es) | 2006-02-03 | 2007-08-31 | Glaxo Group Ltd | Nuevos compuestos |
| US20070232660A1 (en) * | 2006-04-04 | 2007-10-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
| EP2269611B1 (de) | 2006-11-16 | 2016-03-23 | Gemmus Pharma Inc. | EP2- und EP4-Agonisten als Wirkstoffe zur Behandlung von Influenza A Virusinfektionen |
| AU2007331471C1 (en) | 2006-12-15 | 2013-07-25 | Glaxo Group Limited | Benzamide derivatives as EP4 receptor agonists |
| GB0721611D0 (en) | 2007-11-02 | 2007-12-12 | Glaxo Group Ltd | Novel compounds |
| US8063033B2 (en) * | 2008-01-18 | 2011-11-22 | Allergan, Inc. | Therapeutic beta-lactams |
| US8202855B2 (en) | 2008-03-04 | 2012-06-19 | Allergan, Inc | Substituted beta-lactams |
| EP2149551A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors |
| EP2149552A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors |
| EP2149554A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma Aktiengesellschaft | Indolylamide als Modulatoren des EP2-Rezeptors |
| US20110293549A1 (en) | 2009-02-03 | 2011-12-01 | Athena Cosmetics, Inc. | Composition, method and kit for enhancing hair |
| WO2010116270A1 (en) | 2009-04-10 | 2010-10-14 | Pfizer Inc. | Ep2/4 agonists |
| JO3296B1 (ar) * | 2012-06-29 | 2018-09-16 | Lilly Co Eli | مركبات فينوكسي إيثيل بيبريدين |
| CN107802623B (zh) | 2012-07-19 | 2020-10-30 | 开曼化学股份有限公司 | 用于ep4介导的骨相关疾病和病症的二氟内酰胺组合物 |
| WO2014144610A1 (en) | 2013-03-15 | 2014-09-18 | Cayman Chemical Company, Inc. | Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions |
| EP3235817B1 (de) | 2013-03-15 | 2018-12-12 | Cayman Chemical Company, Incorporated | Lactamverbindungen als ep4-rezeptorselektive agonisten zur verwendung bei der behandlung von ep4-vermittelten erkrankungen und zuständen |
| JP6368351B2 (ja) | 2013-03-15 | 2018-08-01 | ケイマン ケミカル カンパニー， インコーポレーテッド | ジフルオロラクタムアナログを合成する方法 |
| JP2016527006A (ja) | 2013-07-19 | 2016-09-08 | ケイマン ケミカル カンパニー， インコーポレーテッド | 骨成長を促進するための方法、システム、及び組成物 |
| ME02896B (de) | 2013-12-17 | 2018-04-20 | Lilly Co Eli | Cyclische phenoxyethylaminderivate und deren aktivität als ep4-rezeptormodulatoren |
| US9540357B1 (en) * | 2014-07-31 | 2017-01-10 | Allergan, Inc. | 15-aryl prostaglandins as EP4 agonists, and methods of use thereof |
| CN114259992B (zh) * | 2021-12-23 | 2023-06-27 | 复旦大学 | 正离子超分子有机框架固体材料在吸附生物毒素中的应用 |
| GB202211232D0 (en) | 2022-08-02 | 2022-09-14 | Heptares Therapeutics Ltd | Prostaglandin EP4 receptor agonist compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4113873A (en) * | 1975-04-26 | 1978-09-12 | Tanabe Seiyaku Co. Ltd. | 8-azaprostanoic acid derivatives |
| DE2528664A1 (de) * | 1975-06-27 | 1977-01-13 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
| US4177346A (en) * | 1976-08-06 | 1979-12-04 | Pfizer Inc. | 1,5-Disubstituted-2-pyrrolidones |
| CA1077948A (en) * | 1976-08-06 | 1980-05-20 | Albin J. Nelson | 1,-5 disubstituted-2-pyrrolidones and processes for their production |
| WO2000038667A2 (en) * | 1998-12-24 | 2000-07-06 | Alcon Laboratories, Inc. | Prostaglandin e agonists for treatment of glaucoma |
| WO2002024647A1 (en) * | 2000-09-21 | 2002-03-28 | Ono Pharmaceutical Co., Ltd. | Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient |
| PT1339678E (pt) * | 2000-11-27 | 2007-11-30 | Pfizer Prod Inc | Agonistas selectivos do receptor ep4 no tratamento de osteoporose |
| US20040254230A1 (en) * | 2001-12-03 | 2004-12-16 | Ogidigben Miller J. | Method for treating ocular hypertension |
-
2003
- 2003-03-06 CA CA002478653A patent/CA2478653A1/en not_active Abandoned
- 2003-03-06 WO PCT/IB2003/000844 patent/WO2003077910A1/en not_active Ceased
- 2003-03-06 JP JP2003575963A patent/JP2005531516A/ja not_active Withdrawn
- 2003-03-06 MX MXPA04005555A patent/MXPA04005555A/es unknown
- 2003-03-06 DE DE60307607T patent/DE60307607T2/de not_active Expired - Fee Related
- 2003-03-06 BR BR0308738A patent/BR0308738A/pt not_active IP Right Cessation
- 2003-03-06 AU AU2003207900A patent/AU2003207900A1/en not_active Abandoned
- 2003-03-06 AT AT03704902T patent/ATE336247T1/de not_active IP Right Cessation
- 2003-03-06 ES ES03704902T patent/ES2268327T3/es not_active Expired - Lifetime
- 2003-03-06 EP EP03704902A patent/EP1487437B1/de not_active Expired - Lifetime
- 2003-03-11 US US10/386,307 patent/US7414071B2/en not_active Expired - Fee Related
- 2003-03-17 TW TW092105829A patent/TW200304816A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003077910A1 (en) | 2003-09-25 |
| JP2005531516A (ja) | 2005-10-20 |
| US7414071B2 (en) | 2008-08-19 |
| BR0308738A (de) | 2005-01-11 |
| EP1487437B1 (de) | 2006-08-16 |
| ES2268327T3 (es) | 2007-03-16 |
| DE60307607D1 (de) | 2006-09-28 |
| CA2478653A1 (en) | 2003-09-25 |
| EP1487437A1 (de) | 2004-12-22 |
| MXPA04005555A (es) | 2005-05-16 |
| TW200304816A (en) | 2003-10-16 |
| DE60307607T2 (de) | 2007-08-09 |
| US20030207925A1 (en) | 2003-11-06 |
| AU2003207900A1 (en) | 2003-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE336247T1 (de) | Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten | |
| ATE375341T1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| CY1109242T1 (el) | Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου | |
| DE602004011394D1 (en) | Thiazolderivate | |
| WO2002009702A8 (en) | Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure | |
| BR0211604A (pt) | Inibidores de integrina para o tratamento de doenças do olho | |
| IS2613B (is) | Útskipt díketópíperasín sem oxýtósínblokkar | |
| ATE398449T1 (de) | Verwendung von azetidincarboxamidderivaten in therapie | |
| DE60234919D1 (de) | 3, 7 oder 3 und 7 thia- oder oxaprostansäure derivate als mittel zur senkung des augeninnendrucks | |
| MY134562A (en) | Methods and compositions to treat conditions associated with neovascularization | |
| US10485786B2 (en) | Pharmaceutical composition for preventing or treating macular degeneration | |
| ATE369348T1 (de) | Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie | |
| EA200400302A1 (ru) | Способ лечения первичной бессонницы | |
| ATE448785T1 (de) | Behandlung von entzündlicher darmerkrankung | |
| ATE425971T1 (de) | Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie | |
| ATE287724T1 (de) | Verfahren zur vorbeugung und behandlung von beschädigung des schleimhautgewebes | |
| EA200200846A1 (ru) | Соединения, полезные для лечения или предупреждения заболеваний, опосредуемых альфа-2в-адреноцептором | |
| DE60003921D1 (de) | Diphenyl-1,2,3-thiadiazol-3-oxide, zusammensetzungen und verfahren zur anwendung | |
| JP2006522777A (ja) | てんかんの治療 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |